The New York Times reports there are nearly 200 investigations into potential theft of intellectual property at biomedical research institutions.
In PNAS this week: gut microbiome-diet relationships in large, East African herbivore species, breast cancer features that boost susceptibility to neoadjuvant chemotherapy, and more.
CNN reports that President Donald Trump is to nominate Stephen Hahn as the next Food and Drug Administration commissioner.
The Associated Press reports that an analysis suggests bison are losing their genetic diversity.
Researchers in the UK uncovered auto-antibodies that might be able to be used to uncover breast cancer, the Guardian reports.
In PLOS this week: computational approach, analysis of chronic granulomas, and more.
A former Duke University biologist who was found to have fabricated data in 39 papers has been banned from receiving federal funding.
The dispute regarding the Wellcome Sanger Institute's use of DNA samples from African individuals could weaken trust between researchers and African populations, Science writes.
The Scientist writes that the announcement of Islamic State's Abu Bakr al-Baghdadi's death suggested that his identity might have been confirmed with rapid DNA testing.
In Science this week: DNA exchange influences diversity among Heliconius butterflies, and more.
The American Association for the Advancement of Science names Sudip Parikh as its next CEO.
New Scientist writes that experimental cancer drug from Amgen appears effective at targeting cancers with KRAS mutations.
PBS NewsHour reports on initiatives that aim to bolster the representation of minority groups in research.
In Nature this week: residual protein expression uncovered for a third of CRISPR targets, and more.
Novartis has paused a trial of its Zolgensma gene therapy that treats spinal muscular atrophy, the Wall Street Journal reports.
The New York Times reports on CRISPR's potential as an antibiotic.
Reuters reports that Scott Gottlieb, the former Food and Drug Administration commissioner, plans to focus in part on new antibiotics in his venture capital role.
In Genome Biology this week: effect of structural variants in cancer, comparison of human and primate gut microbiomes, and more.
The North Jersey Record looks into genetic testing to guide cancer treatment, particularly fluorouracil.
Time magazine discusses Biogen's move to resurrect its Alzheimer's disease drug.
The Guardian reports that birds' eggs may be darker in cooler regions because of how they retain heat.
In PNAS this week: analysis of extensively drug-resistant Mycobacterium tuberculosis strain, regulation of obesity-linked gene, and more.
Science reports a German university found evidence that a researcher who developed a controversial blood test for breast cancer committed misconduct.
In an op-ed at the Washington Post, the University of Pennsylvania's Ravi Parikh writes that research conducted by for-profit companies shouldn't be overlooked.
Wired reviews a new cat DNA testing service, but notes cats are less studied than dogs, affecting how much data can be provided.
Gene editing could be an issue competitive sports need to address soon, four researchers from Arizona State University write at Slate.
A genetic alteration appears to increase heart failure risk among people of African descent, according to the Washington Post.
In his look back at the past decade, BuzzFeed News' Peter Aldhous writes that direct-to-consumer genetic testing has led to "Facebook for genes."
In Nature this week: genetic "clock" that can predict the lifespans of vertebrates, new assembler called wtdbg2, and more.